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Original Article

The impact of preoperative neurological symptom severity
on postoperative outcomes in cervical spondylotic
myelopathy
ABSTRACT
Study Design: The study design is a retrospective cohort study.
Objective: To compare patient‑reported outcomes between patients with mild versus moderate‑to‑severe myelopathy following surgery for
cervical spondylotic myelopathy (CSM).
Summary of Background Data: Recent studies have demonstrated that decompression for CSM leads to improved quality of life when
measured by patient‑reported outcomes. However, it is unknown if preoperative myelopathy classification is predictive of superior postoperative
improvements.
Materials and Methods: A retrospective review of patients treated surgically for CSM at a single institution from 2014 to 2015 was
performed. Preoperative myelopathy severity was classified according to the modified Japanese Orthopaedic Association (mJOA) scale as either
mild (≥15) or moderate‑to‑severe (<15). Other outcomes included neck disability index (NDI), 12‑item short‑form survey (SF‑12), and visual analog
scale (VAS) for arm and neck pain. Differences in outcomes were tested by linear mixed‑effects models followed by pairwise comparisons using
least square means. Multiple linear regression determined whether any baseline outcomes or demographics predicted postoperative mJOA.
Results: There were 67 patients with mild and 50 patients with moderate‑to‑severe myelopathy. Preoperatively, patients with moderate‑to‑severe
myelopathy reported significantly worse outcomes compared to the mild group for NDI, Physical Component Score (PCS-12), and VAS
arm (P = 0.031). While both groups experienced improvements in NDI,
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INTRODUCTION
Cervical spondylotic myelopathy (CSM) is a progressive
disorder associated with spinal cord dysfunction resulting in
loss of motor function, abnormal reflexes, and gait imbalance,
among other symptoms.[1‑3] Optimal timing for the treatment of
CSM remains controversial as the natural history of the disease
can be unpredictable, ranging from stepwise deterioration
and progressive disability to periods of disease quiescence.[4,5]
Conventionally, it was believed that surgical decompression
prevented the progression of myelopathic symptoms without
necessarily improving neurologic function.[6,7] However, recent
studies have since demonstrated that decompression for
CSM leads to improved quality of life when measured by
patient‑reported outcomes.[8‑14] Fehlings et al., prospectively
examined the effect of surgical treatment in patients with
varying degrees of cervical myelopathy severity and found
that patients with mild, moderate, and severe disease all
demonstrated improvements in functional and clinical
outcomes at 1‑year follow‑up. [8] These observations,
however, exposed the need for elucidating the differences
in preoperative myelopathy classification and their utility for
predicting postoperative success.
This study’s primary aim was to investigate whether patients
with moderate‑to‑severe myelopathy undergoing surgery for
CSM experienced greater improvements across the various
health‑related quality of life (HRQOL) outcomes at 1‑year
follow‑up in comparison to patients with mild myelopathy.
We hypothesized that while improvement in neurological
symptoms varies according to baseline myelopathy scores,
surgery for CSM may be warranted despite the degree of
severity, based on the recovery in other patient‑derived
outcomes. We ultimately sought to elucidate the relationship
between preoperative modified Japanese Orthopaedic
Association (mJOA) score and perioperative change in
patient‑reported postoperative outcomes after surgery.
MATERIALS AND METHODS
Study design and data collection
A retrospective review of consecutive patients undergoing
surgery for CSM between 2014 and 2015 was performed.
Patients were identified from a single, large orthopedic
practice with multiple fellowship‑trained orthopedic spine
surgeons. Cervical myelopathy was diagnosed based on
clinical findings including loss of dexterity, ataxia, bowel
and/or bladder symptoms, as well as corresponding physical
examination and concomitant compression of the spinal
cord on advanced imaging studies. Key inclusion criteria
were age 18 years or older at the time of surgery, no prior

cervical spine surgery, and a completed preoperative mJOA
survey. Only those with at least 1‑year worth of outcomes
follow‑up (defined as greater than or equal to 12-months after
the date of index surgery) were included in this study. Patients
with trauma, tumor, infection or those who presented to the
emergency department with central cord syndrome were
excluded. IRB approval was obtained before the start of data
collection.
Outcome measurements
Baseline myelopathy status was classified based on preoperative
mJOA score as mild (mJOA ≥15), moderate (mJOA = 12–14),
or severe (mJOA <12).[7,8,15,16] The mJOA scale is a validated
means to assess degenerative cervical myelopathy relative
to (1) motor dysfunction in the upper extremities, (2) motor
dysfunction in the lower extremities, (3) sensory dysfunction
in the upper extremities, and (4) dysfunction related to
micturition.[15] HRQOL outcome measures included 12‑Item
short form survey (SF‑12), neck disability index (NDI), and
visual analog scale for the neck (VAS neck) and arm (VAS arm)
pain.[15,17‑20] The SF‑12 is a patient‑reported outcome measure
that globally assesses mental and physical functioning.
Both the mental (MCS‑12) and physical (PCS‑12) component
scores of the SF‑12 were included in this study. NDI, which is
reported on a 100‑point scale, is a patient questionnaire that
evaluates the degree that neck pain affects patients’ quality
of life. Lastly, the VAS neck and arm pain scores are based
on an 11‑point numeric rating scale from zero (no pain) to
ten (worst pain imaginable). All patient‑reported outcomes
were prospectively collected in the clinic, remotely via
telephone, or by using the web‑based application Outcomes
Based Electronic Research Database (OBERD, Universal
Research Solutions, Columbia, MO).[21]
Statistical analysis
Data were evaluated for normality by visualization and
computing the skewness and kurtosis. Normally distributed
data were summarized by the mean ± standard deviation;
otherwise, data were summarized by median and interquartile
range. Differences in preoperative outcomes among the
three mJOA severity groups were tested by one‑way analysis
of variance or Kruskal–Wallis tests. If differences were
detected (P < 0.1), post hoc pairwise comparisons with
Bonferroni correction were used to differentiate between
groups. Excluding mJOA, no differences were observed
for preoperative HRQOL outcomes between patients with
moderate and severe myelopathy [Table 1]. Therefore, the two
cohorts were combined and denoted as “moderate‑to‑severe”
myelopathy for further comparative analysis.
Baseline comparisons between the “mild‑” and
“moderate‑to‑severe” groups were performed for sex,
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Table 1: Differences in preoperative patients reported outcomes grouped by mJOA
Mild (n=67)
mJOA
NDI
PCS‑12
VAS Arm
MCS‑12
VAS Neck

17 [15,18]
28.5 (17.6)
36.9 (8.3)
4.0 [0.7, 7.5]
52.9 [44.4, 59.2]
3.3 [0.4, 7.0]

Moderate
(n=37)

Severe (n=13)

14 [13, 14]
39.5 (19.8)
32.9 (7.7)
7.0 [3.5, 8.8]
46.5 [38.1, 57.9]
5.0 [3.0, 7.5]

10 [7, 11]
44.0 (16.7)
27.4 (6.0)
6.2 [5.0, 7.2]
43.0 [39.1, 59.6]
3.4 [1.0, 8.0]

Overall

Mild vs. mod

<0.001
0.002
<0.001
0.064
0.205
0.246

<0.001
0.012
0.043
0.039
0.147
0.141

P*
Mild vs. sev
<0.001
0.018
<0.001
0.307
0.449
1.000

Mod vs. sev
0.032
1.000
0.100
1.000
1.000
0.736

*Differences in preoperative patient‑reported outcomes across the three original mJOA groups (mild, moderate, severe) were tested with one‑way ANOVA or Kruskal‑Wallis tests, as
appropriate. Significant P<0.05 are reported for the overall cohort, mild versus moderate (mod), mild versus severe (sev), and moderate versus severe myelopathy

age, body mass index (BMI), number of levels fused, type
of surgery (anterior fusion, posterior fusion, combined
anterior and posterior fusion, laminoplasty alone), and
length of follow‑up. Categorical variables were tested using
Chi‑square tests, while continuous variables were tested
using Mann–Whitney U or t‑tests.
Differences in patient‑reported outcomes between groups
over time were tested by linear mixed‑effects models for age,
myelopathy severity, time, and group‑by‑time interaction
with repeated measures on time and subject‑level random
intercept. Model residuals were examined for normality on a
Q‑Q plot. From the mixed‑effects model, pairwise comparisons
using least‑square means with Bonferroni correction tested
for differences within each group over time and between
groups at each time‑point. Results were summarized by the
model estimates with 95% confidence intervals (CIs). Finally,
multiple linear regression analysis determined whether any
preoperative outcomes or baseline demographics predicted
postoperative mJOA. Statistical significance was determined
at α = 0.05. All statistical analyses were performed using
R software (Version 3.6.1; The R Foundation for Statistical
Computing Platform; Vienna, Austria).
RESULTS
Preoperative outcomes according to modified Japanese
Orthopaedic Association classification
There were 117 patients that met inclusion criteria. Table 1
summarizes preoperative outcomes initially stratified by
mild, moderate, and severe myelopathy. NDI was significantly
higher among patients with moderate myelopathy (P = 0.012)
and severe myelopathy (P = 0.018) compared to patients
with mild myelopathy. PCS‑12 exhibited a similar pattern
with the moderate (P = 0.043) and severe (P < 0.001)
groups reporting worse scores than the mild group. VAS
arm was significantly higher in the moderate than the mild
group (P = 0.039). As previously mentioned, because no
there was no difference in preoperative outcomes between
the moderate and severe patients, the two cohorts were
combined (moderate‑to‑severe) for further analysis.
96

Baseline characteristics of cohort
Baseline demographics for mild and moderate‑to‑severe
groups are shown in Table 2. Preoperatively, there were
67 (57.3%) patients with mild myelopathy, and 50 (42.7%)
with moderate‑to‑severe myelopathy (37 moderate, 13
severe). Mean age was 55.8 ± 11.9 years, and mean BMI was
29.9 ± 6.4. Patients with moderate‑to‑severe myelopathy
were significantly older (60.3 vs. 52.4 years, P < 0.001).
Median follow‑up was 23.0 (12.9, 23.4) months with 100%
of patients having at least 1‑year follow‑up. Notably, 53.0%
of patients in the cohort had at least 2‑years of outcomes
follow‑up. There was a longer follow‑up observed in the
moderate‑to‑severe group (23.1 vs. 19.8 months, P = 0.031).
After calculating Pearson’s correlation coefficient between
the length of follow‑up and outcomes, only MCS‑12
and PCS‑12 exhibited weakly positive correlations of
0.24 (P = 0.019) and 0.17 (P = 0.099), respectively, in
relation to follow‑up length. There was no significant
correlation between length of follow‑up and changes in
mJOA scores (P = 0.363).
Overall, anterior cervical discectomy and fusion (ACDF)
was the most common procedure (88 patients), followed
by posterior cervical discectomy and fusion (16 patients),
combined anterior and posterior procedure (eight patients),
and laminoplasty alone (five patients) [Table 2]. There were
no significant differences in the number of levels fused or in
the surgical approach between myelopathy groups. Three (3)
patients underwent revision surgery during the follow‑up
period. Initial procedures, myelopathy severity status, and
corresponding revisions surgeries for the three patients
were as follows:
1. Primary: C3‑7 ACDF; moderate myelopathy revision:
C6‑T1 laminoforaminotomies on postoperative day (POD)
185 for worsening radiculopathy
2. Primary: C3‑7 laminectomies with posterolateral fusion
and placement of segmental instrumentation; severe
myelopathy revision: C2 laminectomy on POD 485 for
cervical stenosis
3. Primary: C3‑7 ACDF; moderate myelopathy revision:
Anterior C5 and C6 corpectomy, revision of prior
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Differences in outcomes between myelopathy classification
groups
Preoperatively, the moderate‑to‑severe group reported
significantly worse outcomes compared to the mild group
for NDI (+14.3, P < 0.001), PCS‑12 (‑4.5, P = 0.031), and VAS
Arm (+2.0, P = 0.005) [Table 4 and Figure 1]. Postoperatively,
mJOA was the only outcome that remained significantly
worse in the moderate‑to‑severe group compared to the
mild group (P = 0.017) [Table 4 and Figure 2]. Median
mJOA scores after surgery were 17 and 16 for the mild and
moderate‑to‑severe groups, respectively [Table 3].

C3‑C7 ACDF, and addition of posterior spinal fusion
instrumentation from C2‑T2 on POD 11 due to failure
of the anterior plate with resultant cervical kyphosis.
Changes in outcomes after surgery
Due to the significant difference in age between the two
myelopathy severity groups, age was included in the mixed
effect models. Estimates from the pairwise comparisons
are summarized in Tables 3 (overtime within groups) and
4 (between groups within time). A positive value indicates an
increase from preoperative to postoperative score in Table 3
and that the moderate‑to‑severe group reported greater
scores than the mild group in Table 4.

A multiple linear regression model was constructed to
predict postoperative mJOA. Both greater preoperative
mJOA (P < 0.001, β‑coefficient = 0.37, 95% CI: 0.22, 0.53)
and younger age (P = 0.017), β‑coefficient = −0.05, 95%
CI:‑0.08, −0.01) predicted greater mJOA at final follow‑up.

Absolute preoperative and postoperative scores are
summarized for each group in Table 3. Overall, patients in
both the mild and moderate‑to‑severe myelopathy groups
experienced significant improvements across all HRQOL
measurements as a result of surgery. Both groups reported
significant improvement in NDI, PCS‑12, VAS arm, and VAS
neck. Only the moderate‑to‑severe group reported significant
improvement in mJOA (P < 0.001) and MCS‑12 (P = 0.014).

DISCUSSION
It has been conventionally understood that the utility of
surgery for CSM lies not in improving myelopathy, but instead
in halting disease progression. For this reason, the treatment

Table 2: Patient demographics overall and grouped by
myelopathy severity

Female Sex
Age
BMI
Months follow‑up
No. levels fused
Approach
Anterior
Posterior
Anterior/Posterior
Laminoplasty

Mild (n=67)

Moderate‑to‑
severe (n=50)

Between
groups (P)1

29
52.4 (11.3)
29.0 (5.52)
19.8 [12.8;23.2]
2 [2;3]

21
60.3 (11.2)
31.0 (7.37)
23.1 [16.4;23.9]
3 [2;4]

1.000
<0.001
0.118
0.031
0.267

54
8
4
1

34
8
4
4

0.291

Figure 1: Comparison of preoperative patient reported outcome measures
between patients with mild versus moderate‑to‑severe myelopathy.
Modified Japanese Orthopaedic Association, PCS‑12, MCS‑12 = higher is
better. Neck disability index, visual analog scale neck, visual analog scale
arm = lower is better. *P < 0.05 when comparing outcomes between the
two myelopathy groups

Baseline comparisons between the two myelopathy classification groups (mild versus
moderate‑to‑severe) tested for differences in gender, age, BMI, number of levels
fused, type of surgery, and length of follow‑up in months. 1Categorical variables were
tested using Chi‑square tests while continuous variables were tested using t‑tests or
Mann‑Whitney U tests, as appropriate.

Table 3: Changes in outcome scores over time grouped by myelopathy severity
Outcome
mJOA
NDI
PCS‑12
VAS Arm
MCS‑12
VAS Neck

Mild
Pre

Post

Estimate1

P

Pre

17 [15,18]
28.5 (17.6)
36.9 (8.3)
4.0 [0.7, 7.5]
52.9 [44.4, 59.2]
3.3 [0.4, 7.0]

17 [16, 18]
16.0 (18)
44.6 (8.9)
0.8 [0.0, 2.7]
57.1 [48.4, 60.4]
1.1 [0.0, 4.1]

+0.4 [‑0.4, 1.1]
‑11.8 [‑18.4, ‑5.2]
+7.9 [4.4, 11.5]
‑2.3 [‑3.7, ‑0.9]
+1.8 [‑2.6, 6.1]
‑1.6 [‑2.9, 0.4]

0.726
<0.001
<0.001
<0.001
1.000
0.003

13 [11, 14]
40.7 (19.0)
31.5 (7.7)
6.6 [3.6, 8.8]
46.1 [38.2, 58.1]
4.4 [2.0, 7.7]

Moderate‑to‑severe
Post
Estimate1
16 [13, 18]
19.9 (17.6)
40.7 (9.8)
1.8 [0.0, 4.4]
55.8 [47.6, 60.1]
1.4 [0.0, 2.5]

+3.1 [2.3, 4.0]
‑20.4 [‑28.0, ‑12.7]
+9.6 [5.4, 13.7]
‑3.4 [‑5.0, ‑1.8]
+5.7 [0.6, 10.7]
‑2.9 [‑4.3, ‑1.4]

P
<0.001
<0.001
<0.001
<0.001
0.014
<0.001

Preoperative and postoperative scores for each mJOA group are reported as mean or median as appropriate. Using a mixed effects model controlling for patient age at time of
surgery, pairwise comparisons with Bonferroni correction tested for differences within each myelopathy classification group over time. 1Estimates from the pairwise comparisons are
reported with the 95% confidence interval and adjusted P. Positive values for the estimate indicate an increase in score values from preoperatively to postoperatively.
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Table 4: Differences in preoperative and postoperative
outcomes between myelopathy groups
Outcome

mJOA
NDI
PCS‑12
VAS Arm
MCS‑12
VAS Neck

Moderate‑to‑severe versus mild myelopathy
Preoperative
Postoperative
P
Estimate1
P
Estimate1
‑4.0 [‑4.9, ‑3.0]
14.3 [4.9, 23.7]
‑4.5 [‑8.9, ‑0.0]
2.0 [0.4, 3.6]
‑5.1 [‑10.9, 0.7]
1.2 [‑0.3, 2.7]

<0.001
<0.001
0.031
0.005
0.079
0.114

‑1.2 [‑2.3, ‑0.1]
5.7 [‑4.4, 15.9]
‑2.9 [‑7.8, 2.0]
0.9 [‑0.9, 2.7]
‑1.2 [‑7.5, 5.1]
0.2 [‑1.6, 1.7]

0.017
0.535
0.481
0.797
1.000
1.000

Differences in each patient‑reported outcome between mJOA classification groups
over time were tested by linear mixed effects models for age, group, time, and the
group by time interaction with repeated measures on time and subject‑level random
intercept and controlling for patient age at time of surgery. From the mixed effects
model, pairwise comparisons with Bonferroni correction tested for differences between
groups at each time‑point. 1Estimates from the pairwise comparisons are reported with
the 95% confidence interval and adjusted P. A positive coefficient indicates that the
moderate‑to‑severe group reported higher scores than the mild group.

of structured rehabilitation. [25] Our results corroborate
the current literature that those with moderate‑to‑severe
myelopathy have worse preoperative symptoms at baseline
and have more to gain postoperatively.[8,23,26‑28] Khan et al.,
while studying the trajectory of postoperative neurological
improvements in patients with CSM, concluded that
in the short term (3 months) all patients, regardless of
preoperative mJOA severity, improved significantly. However,
only patients with severe findings exhibited progressive
improvement over the longer term (12 months), while
mild and moderate patients appeared to plateau.[23] Our
results were comparable, as patients with worse symptoms
achieved statistically significant improvement among all six
outcome measures with larger deltas, while those with mild
symptoms had fewer and smaller improvements. However,
our findings demonstrate that patients with CSM, regardless
of myelopathy severity, ultimately achieved better outcome
scores at 1‑year follow‑up. Those with mild myelopathy in this
cohort maintained significantly better mJOA scores than more
severe counterparts after 1‑year, despite the ceiling effect.

algorithm for CSM often differs between patients with mild
and those with moderate‑to‑severe myelopathy; the premise
being that patients with mild myelopathy have less to gain
neurologically.[22] This observation can be attributed to the
ceiling effect, where patients with mild myelopathy can only
improve 1–3 points on the mJOA given the questionnaire’s
inherent limit.[8,23] However, neurological improvement
after surgery must also take into account other outcomes
desired by patients, including physical and psychological
well‑being.[24]

Our findings suggest that patients do not achieve normal
function by simply deferring surgery until the onset of
moderate‑to‑severe myelopathy and intervening sooner may
potentially preserve higher neurological function. The length
of time between mild and moderate‑to‑severe CSM can be
progressive, stepwise, or stagnant, thus patients’ response
to nonoperative treatment is classically unpredictable.[4,13,29‑34]
Patients with more severe symptoms are more likely to have
greater cord compression, which has been intimately linked
to irreversible spongiform change, grey matter necrosis,
cavitation, and other cellular‑level abnormalities observed in
histological studies.[35,36] Furthermore, Wada et al.,’ formative
study of CSM magnetic resonance images, demonstrated that
T2 signal intensity changes in the intramedullary canal were
indicative of permanent damage and correlated with worse
outcomes.[37] While those with mild myelopathy certainly
have less to gain secondary to the ceiling effect, they also
have much more to lose in outcomes and cord morphology
as they wait for the natural history of their disease to take
hold. We suggest that the degree of myelopathy alone should
not be the guiding principle for determining whether or not
a patient is a candidate for surgery.

The most current clinical guidelines for managing cervical
myelopathy were published by Fehlings et al., [25] For
patients with moderate or severe CSM, there was a strong
recommendation for surgical intervention based on the
moderate quality of evidence.[25] Comparatively, for patients
with mild myelopathy, there was a weak recommendation
based on poor evidence to offer either surgery or a trial

When determining surgical indications, we advocate for a
more patient‑centered approach that weighs the risks and
benefits of operative intervention and the totality of symptoms
experienced from CSM. Despite efforts to standardize
patients’ subjective experiences, contemporary reviews have
largely concluded that no single measurement is predictive for
all cases of CSM.[28,38,39] McGregor et al., in a recent prospective

Figure 2: Comparison of postoperative patient reported outcome measures
between patients with mild versus moderate‑to‑severe myelopathy.
Modified Japanese Orthopaedic Association, PCS‑12, MCS‑12 = higher is
better. Neck disability index, visual analog scale neck, visual analog scale
arm = lower is better. *P < 0.05 when comparing outcomes between the
two myelopathy groups

98

Journal of Craniovertebral Junction and Spine / Volume 13 / Issue 1 / January‑March 2022

[Downloaded free from http://www.jcvjs.com on Tuesday, April 12, 2022, IP: 147.140.233.15]

Toci, et al.: Preoperative symptom severity in cervical myelopathy

study, attempted to correlate patient‑derived myelopathy
scores based on mJOA and physician‑derived scores based
on the American Spine Injury Association (ASIA) summary
physical exam.[24] While they found that patients experienced
improvements in disability and physical function after surgery,
mJOA and ASIA were weakly correlated.[24] Their findings
exemplify how patients’ perception of their disease can be
incongruent with their surgeons’ perception. Altogether, the
present study and evidence from the literature suggest that
treatment optimization for CSM requires shared decision
making that weighs objective clinical findings, subjective
patient experience, potentially irreversible sequelae from
pursuing conservative management, and risks of surgical
intervention.[8,24,26‑28,40]
Our study is not without limitations. For instance, about
22% of patients were lost to follow‑up during the 1‑year
period of this cohort, which is comparable to previous
studies.[41‑43] In addition, while the levels operated on were
similar across groups, no data was collected as to the specific
components used in each case. There is growing literature
that certain low‑profile implants may exert a stronger effect
size on patient outcomes than previously thought.[44] The
generalizability of this study may also be limited by the
potential confounding between preoperative neurological
function and age as shown on regression analysis. The
effect of age on outcomes was more evident at the extremes
(<40 or >70 years of age) but insignificant between the ages
of 40 and 70. Another potential limitation is the absence
of a control group, but our intent was to make a direct
comparison within patients diagnosed with CSM based on the
severity of symptoms and not normal subjects. Fehlings et al.,
have even proposed that the use of controls in prospective
studies involving patients with CSM may be confounded by
the number of patients that potentially deteriorate and end
up being surgical candidates.[8] We also recognize that the
similarities in postoperative MCS‑12 scores between the
myelopathy groups could be attributed to the longer length of
follow‑up observed in the moderate‑to‑severe cohort. Finally,
due to few patients with severe myelopathy (mJOA <12),
and the similarities observed in functional and pain scores,
patients with severe CSM had to be grouped with those
who presented with moderate symptoms for comparative
analysis. Thus, the results of our study may not be specifically
generalizable to patients with severe myelopathy.
Conclusion

Currently, there is no consensus on managing patients
with mild myelopathy, whereas surgical intervention is
recommended for patients with moderate‑to‑severe disease.
This study indicates that when compared to those with
moderate‑to‑severe CSM, patients with mild myelopathy
maintain closer to normal neurologic function and significant
improvements in other quality of life, disability, and
pain‑related outcome measures when treated surgically.
Patients with moderate‑to‑severe myelopathy, who are likely
to have greater irreversible spinal cord changes, do not
achieve normal absolute function even after surgery. As such,
early surgical intervention should be strongly considered in
patients with mild myelopathy if they seek to benefit from
the observed recovery in HRQOL outcome measures and
forego potentially irreversible sequelae from progressive
cervical degeneration.
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